title: Radiotherapy in marginal zone lymphoma.
abstract: OBJECTIVE
  To evaluate the efficacy of radiotherapy (RT) for early-stage nodal and extranodal marginal zone lymphoma (MZL).
  
  
  METHODS
  Patients with stage I (n = 22) and stage II (n = 8) MZL, who were treated with RT were reviewed. The primary tumor localisation was in the orbita (n = 12), stomach (n = 8), head and neck other than the orbita (n = 8), breast (n = 1) and one case of marginal zone lymphoma of the skin (n = 1). The median radiotherapy dose was 40 Gy (5 to 45 Gy).
  
  
  RESULTS
  The median follow-up time was 103 months. The 5-year overall survival and event-free survival rates were 85 ± 7% and 71 ± 9%, respectively. There was no infield recurrence. Recurrence occurred outside of the radiation field in six patients. The relapses were treated with salvage RT and had excellent local control (100%) at five years after salvage RT.
  
  
  CONCLUSIONS
  Localized extranodal MZL have an excellent prognosis following moderate-dose RT. RT is also an effective salvage therapy in cases of localized recurrence. Further clinical studies should evaluate the optimal dose for MZL.
authors.affiliation: Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
authors.forename: Kristin
authors.initials: K
authors.lastname: Deinbeck
authors.forename: Hans
authors.initials: H
authors.lastname: Geinitz
authors.forename: Bernhard
authors.initials: B
authors.lastname: Haller
authors.forename: Khashayar
authors.initials: K
authors.lastname: Fakhrian
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011879:Radiotherapy Dosage; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods; D013997:Time Factors; D016896:Treatment Outcome